Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer

BMC Cancer

Table 4 Univariate and multivariate analysis with axillary lymph node metastasis for cT1 breast cancer

Parameters	Univarite analysis			Multivarite analysis
Parameters	Odds ratio	95% CI	p value	Odds ratio	95% CI	p value
Age at operation (years old)
≤ 60 vs > 60	0.967	0.645–1.451	0.872
Tumor size (mm)
≤ 10.0 vs > 10.0	3.225	1.825–5.700	< 0.001	2.352	1.337–4.391	0.003
Estrogen receptor
Negative vs Positive	1.266	0.694–2.312	0.441
Progesterone receptor
Negative vs Positive	1.483	0.978–2.248	0.063	1.457	0.945–2.269	0.089
HER2
Negative vs Positive	0.965	0.477–1.953	0.920
Ki67
≤ 20% vs > 20%	1.092	0.656–1.818	0.734
Intrinsic subtype HR + BC
No vs Yes	1.536	0.792–2.979	0.201
Intrinsic subtype HR-HER2 + BC
No vs Yes	0.940	0.319–2.773	0.911
Intrinsic subtype TNBC
No vs Yes	0.566	0.252–1.269	0.162
Lymph vascular invasion
No vs Yes	4.595	3.018–6.995	< 0.001	3.891	2.529–6.016	< 0.001
Hyperlipidemia
No vs Yes	0.710	0.413–1.218	0.212
Multiple medicine types for hyperlipidemia
No vs Yes	1.821	0.363–9.140	0.460
Statins
Non-user vs User	0.705	0.400–1.243	0.226
Lipophilic statins
Non-user vs User	0.357	0.127–0.996	0.042	0.384	0.113–0.987	0.048
Hydrophilic statins
Non-user vs User	1.115	0.578–2.148	0.746
Fibrate
Non-user vs User	0.599	0.075–4.772	0.624
Nicotinic acid (tocopherol acetate)
Non-user vs User	2.189	0.419–11.426	0.341
Sterol absorption inhibitors (ezetimibe)
Non-user vs User	1.085	0.125–9.373	0.941

HER2 Human epidermal growth factor receptor 2, HR + BC Hormone receptor-positive breast cancer (ER+ and/or PgR+), HR-HER2 + BC Human epidermal growth factor receptor 2-enriched breast cancer (ER-, PgR-, and HER2+), TNBC Triple negative breast cancer (ER-, PgR-, and HER2-), CI Confidence intervals

ISSN: 1471-2407